• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CryoLife, Inc.

    10/7/21 9:56:04 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care
    Get the next $CRY alert in real time by email
    DEFA14A 1 cryo-defa14a_111621.htm ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material Pursuant to §240.14a-12

    CRYOLIFE, INC.

    (Name of Registrant as Specified in Its Charter)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒No fee required.
    ☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    (1)Title of each class of securities to which transaction applies:
     
    (2)Aggregate number of securities to which transaction applies:
     
    (3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
     
    (4)Proposed maximum aggregate value of transaction:
     
    (5)Total fee paid:
     
    ☐Fee paid previously with preliminary materials.
    ☐Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)Amount Previously Paid:
     
    (2)Form, Schedule or Registration Statement No.:
     
    (3)Filing Party:
     
    (4)Date Filed

     

     

     

    Important Notice of Availability of Materials for the Special Stockholder Meeting of

     image

    To Be Held On:

     

    November 16, 2021 at 9:00 a.m. Eastern Time

     

    Meeting live via the Internet – please visit https://web.lumiagm.com/295739807 (password: cryolife2021)

     

     

    COMPANY NUMBER

     

     

    ACCOUNT NUMBER

     

     

    CONTROL NUMBER

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

    If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy.  To facilitate timely delivery please make the request as instructed below before 11/2/2021.

    Please visit http://www.astproxyportal.com/ast/01609/special, where the following materials are available for view: 

     

    ● Notice of Special Meeting of Stockholders

     

    ● Proxy Statement

     

    ● Form of Electronic Proxy Card

     

     

    TO REQUEST MATERIAL:

    TELEPHONE:  888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers)

    E-MAIL:  [email protected]

     

    WEBSITE:  https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials

    TO VOTE:

    image

    ONLINE: To access your  online  proxy  card,  please  visit  www.voteproxy.com and  follow  the  on-screen instructions or scan the QR code  with your smartphone.  You may enter  your voting instructions at www.voteproxy.com up until 11:59  PM EDT the day before the meeting date.

     

    VIRTUALLY AT THE MEETING: The  company will be  hosting the  meeting live via the  Internet this year. To attend the meeting via the Internet, please visit https://web.lumiagm.com/295739807 (password: cryolife2021) and  be  sure to have  your control number available.

     

    TELEPHONE: To vote  by telephone, please visit www.voteproxy.com to view the  materials and  to obtain the toll free number to call.

     

    MAIL: You may request a card  by following the instructions above.

     

     

     

     

    1.

    To  approve the  reincorporation  of CryoLife,  Inc.  from  the  State of Florida  to  the  State of Delaware,  including   the  Plan  of  Conversion,  Florida  Articles  of  Conversion,   Delaware Certificate of Conversion, Delaware Certificate of Incorporation, and  Delaware Bylaws.

         

     

    2.

    To  approve  an  exclusive  forum  provision   as  set  forth  in  the   Delaware  Certificate  of Incorporation to take  effect following the Reincorporation.

     

     

     

     

    3.

    To approve an adjournment of the meeting, if necessary, to solicit additional proxies if there are  not  sufficient  votes in  favor  of the  Reincorporation  Proposal  or  the  Exclusive  Forum Proposal.

     

     

     

     

     

     

     

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSALS 1, 2 AND 3.

     

     

     

     

    Please note that you cannot use this notice to vote by mail.

     

     

     

     

     
    Get the next $CRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRY

    DatePrice TargetRatingAnalyst
    1/7/2022$29.00 → $25.00Equal-Weight
    Morgan Stanley
    7/30/2021$31.00 → $32.00Equal-Weight
    Morgan Stanley
    7/30/2021$38.00 → $39.00Buy
    Needham
    7/15/2021$31.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/10/21 4:13:01 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/1/21 4:14:23 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)

    4 - CRYOLIFE INC (0000784199) (Issuer)

    11/30/21 4:40:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CryoLife Announces Corporate Rebranding and Changes Name to Artivion

    ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

    1/18/22 8:10:00 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,

    11/9/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously

    1/7/22 8:57:55 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously

    7/30/21 11:55:50 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Cryolife with a new price target

    Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously

    7/30/21 6:09:23 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    SEC Filings

    View All

    CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    1/20/22 4:36:16 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    8-A12B/A - CRYOLIFE INC (0000784199) (Filer)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CRYOLIFE INC (0000784199) (Filer)

    1/4/22 3:58:05 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Leadership Updates

    Live Leadership Updates

    View All

    Anthony Semedo Joins CryoLife Board of Directors

    ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali

    9/22/21 4:25:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Financials

    Live finance-specific insights

    View All

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

    ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes

    10/20/21 4:10:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Second Quarter 2021 Financial Results

    ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i

    7/29/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed

    SC 13G - CRYOLIFE INC (0000784199) (Subject)

    2/11/21 2:02:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care